While several molecular targets have been investigated in clinical trials, only HER2-targeted trastuzumab and immune checkpoint inhibitors such as pembrolizumab or nivolumab have demonstrated effective response rates and been established as standard first-line therapies for advanced GC [3, 4]. Here, ERBB2 is linked to gastric cancer.